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tasis was 10.9 ± 8.9 months. The percentages of patients receiving at least one of these 
therapies increased from 10.5% in 2005 to 74% in 2008. Sunitinib use showed consis-
tent increase from 0% in 2005 to 50% in 2008. Sorafenib with zero use in 2005 
increased to 25% in 2006 but decreased thereafter to 11.7% in 2008. Interferon-alpha 
(range: 5–8%) and bevacizumab (range: 2–4%) use remained relatively stable during 
the observation period, whereas interleukin-2 and temsirolimus was used rarely (≤1%) 
and everolimus not used at all. CONCLUSIONS: Pharmacologic agents were increas-
ingly used to treat mRCC patients in recent years. Targeted therapies have become the 
main modality of treatment, with sunitinib accounting for most of the growth.
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OBJECTIVES: There is no evidence about real medical practice in oncology in 
Mexico. The objective of this study was to explore current medical practices of 
Mexican oncologists in the management of ﬁve malignancies: breast, non-small cell 
lung (NSCL), colon, rectum and kidney cancer. METHODS: A speciﬁc instrument for 
these malignancies was designed, validated and applied to Mexican oncologists. Infor-
mation requested reﬂects stage-speciﬁc treatment and disease management, including 
surgery and drugs uses, as well as frequency of prescription, discontinuation and 
factors that determines them in public and private health care institutions, between 
January-April 2009. RESULTS: 30 oncologists were included: 63.3% from Instituto 
Mexicano del Seguro Social and 20.0% from Instituto Nacional de Cancerología. 
73.3% of all oncologists have public and private practices. Tamoxiphen (adjuvant 
hormonoterapy) and 5-ﬂuoroacil/epirubicin/cyclophosphamide (adjuvant, neoadju-
vant and palliative chemotherapy) are the most frequently drug schemes used in breast 
cancer, with no differences between public and private practices(p < 0.05). At least 
85.0% of NSCL cancer cases are diagnosed in IIIA and IV stages; combination che-
motherapy (platinum/etoposide) is highly prescribed in NSCL cancer patients undergo-
ing radiotherapy or non-resectable disease. Colon cancer is diagnosed in stages 
III(58.0%) and IV (14.0%); 20.0% of colon cancer patients undergoes surgery (left 
or right hemicolectomy). Drug availability and medical guidelines recommendations 
drive prescription to treat colon cancer. Surgery in rectum cancer is applied at stages 
IIB, IIIA and IIIB (17.6%, 20.0% and 16.9%, respectively). Rectum cancer presents 
as non-resectable disease in 60.0% of cases in stage IV. Drugs used to treat metastatic 
renal cells cancer are interferon-α (80.0%) and sunitinib(19.0%), prescription is 
driven by drug availability and efﬁcacy, respectively. Discontinuation rate of inter-
feron-α due adverse event was 90.0%. CONCLUSIONS: Knowledge of oncology 
current medical practice provides a basis for evaluation, as well as supports decision 
making process and the generation of new strategies for policy makers.
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COLORECTAL CANCER HOSPITAL ADMISSIONS IN WEST VIRGINIA 
FROM 2003 TO 2007
Shah N, Halverson J
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Colorectal cancer (CRC) is the third most common form of cancer in 
men and women in West Virginia. Hospitalization followed by surgical resection is 
the standard curative treatment. The aim of this study is to examine colorectal cancer 
hospitalizations and common comorbidities and evaluate associated outcomes during 
2003–2007 in West Virginia. METHODS: Data from the Healthcare Cost and Utiliza-
tion Project (HCUP), State Inpatient Database were investigated. Comorbidities were 
identiﬁed using comorbidity software provided by HCUP. Descriptive statistics for 
hospitalizations with a primary or secondary diagnosis of CRC were tabulated. Mul-
tivariate regressions were used to compare for differences in the outcomes including 
length of stay, total charges, and in-hospital deaths. RESULTS: There were 6919 
admissions with a primary or secondary diagnosis of CRC of which 27.4% were 
emergency admissions. The most common comorbidity was diabetes (18.5%), fol-
lowed by COPD and hypertension (both 3.7%). Volume depletion disorder (3.5%) 
followed by pneumonia (2.4%) and malignant neoplasm of the liver (2.3%) were the 
most common primary diagnoses seen when CRC was the secondary diagnosis. Mean 
length of stay was signiﬁcantly higher for admissions with a primary diagnosis (9.2 
days versus 4.8 days, p < 0.001). Mean total charges were also higher for primary 
diagnosis (28,618.94 USD versus 12,195.22 USD, p < 0.001). For the 356 (5.1%) 
in-hospital deaths, emergency admissions had odds ratio (OR) of 2.50 (95% CI, 
2.01–3.10), and primary diagnosis of CRC had OR of 1.64 (95% CI, 1.30–2.08). 
Admissions with comorbid diabetes formed 12.6% (45) of patients who died in the 
hospital. CONCLUSIONS: Signiﬁcant resources are consumed by CRC hospital 
admissions. A large percentage of CRC hospitalizations are emergency admissions 
indicating advanced disease and possibly failure of timely screening. Diabetes was the 
most common comorbid condition and further investigation in diabetics is needed to 
check screening behavior and access to screening centers.
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OBJECTIVES: Triple negative (TN) breast cancer (BC), a subtype of BC characterized 
by its unique molecular proﬁle and aggressive clinical behavior, lacks satisfactory 
standard therapies. Little is known about how patients with TNBC were treated in 
community practice. This study was conducted to identify treatment patterns of ﬁrst-
line chemotherapy (CT) of TNBC using data from community practices. METHODS: 
Analyses were conducted using the Georgia Cancer Specialist Database (GCSD 2003–
2008) and the International Oncology Network’s Treatment and Outcomes Database 
(ION 2003–2008). In both data, patients with stage IV TNBC were selected and fol-
lowed for up to one year since initial diagnosis. The ﬁrst-line CT was identiﬁed if 1) 
the ﬁrst drug was initiated within 120 days following the initial BC diagnosis; 2) other 
combination drugs be started within 30 days of the ﬁrst drug. RESULTS: The study 
included 30 and 35 patients from GCSD and ION, respectively. In GCSD sample, 14 
patients (47%) were treated with monotherapy, capecitabine and taxanes being domi-
nant (50% and 43%, respectively); 16 patients treated with combination therapy, with 
carboplatin/gemcitabine+paclitaxel (C/G+P) and cyclophosphomide+doxorubicin 
(CP+DOX) most frequently used regimens or backbone therapies (31% for each). 
Other drugs used in combination included docetaxel, bevacizumab, 5-FU and albu-
min-bound P. Similar patterns were found in ION sample with some deviations: 20 
patients (57%) treated with monotherapy, taxanes being dominant (70%); 15 patients 
treated with combination therapy, C/G+P and CP+DOX/+epirubicin were the most 
frequently used regimens or backbone therapies (33% for each). Other drugs used in 
combination included docetaxel, 5-FU, bevacizumab, lapatinib and methotrexate. 
CONCLUSIONS: It appears that taxanes/capecitabine, and C/G+P or CP+DOX were 
mostly used monotherapy and combination therapy, respectively, for stage IV TNBC. 
The patterns are rather diverse than convergent, reﬂecting lack of standard therapy 
for TNBC. Data from other community settings are needed to conﬁrm these results.
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IMPROVING ASCERTAINMENT OF VITAL STATUS USING SOCIAL 
SECURITY DEATH MASTER FILE (SSDMF) AND THE NATIONAL DEATH 
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BACKGROUND: Ascertainment of vital status is critical to studies in many disease 
areas especially in oncology. Two commonly used sources for mortality are SSDMF 
and NDI, with NDI considered the gold standard. Limitations identiﬁed in previous 
studies are under-ascertainment associated with the former; time lag (1–2 years) and 
higher cost associated with the latter. OBJECTIVES: To compare ascertainment of 
vital status by consolidating mortality data from SSDMF and NDI vs. either source 
alone. METHODS: Patient identiﬁers for a cohort of 3761 cancer patients from a 
large US claims database were submitted to SSDMF (cutoff February 2009) and NDI 
(cutoff December 2007) to obtain vital status. Matching to SSDMF utilized SSN alone 
or a combination of last name, ﬁrst name and birthdate. Matching to NDI utilized 
combinations of SSN and/or patient name, birthdate, and state of residence. For 
patients with a death date found in NDI, a variable indicating a true or false match 
was provided by NDI based on the probabilistic score. We derived the death date via 
a stepwise approach by utilizing all match results from either source. RESULTS: Of 
3761 patients, SSDMF returned a match for 901 (24%) patients using SSN alone, and 
1088 (29%) patients using the combination. From the NDI, 946 (25%) patients had 
a “true” match, 1408 (37%) had a “false” match, and remainder were considered 
alive. Comparing SSDMF and NDI results utilizing both true and false NDI matches, 
we derived death dates for 1326 patients, which is 47% and 40% more compared to 
SSDMF match by SSN alone or NDI true match, respectively. Eight patients had claims 
following death date and were considered false matches. CONCLUSIONS: Utilizing 
all match results from SSDMF and NDI identiﬁed signiﬁcantly more deceased patients 
compared to either source alone. Misclassiﬁcation of living patients as deceased 
appears minimal as veriﬁed by claims.
PCN157
METHODOLOGIC ISSUES OF IDENTIFYING FEBRILE NEUTROPENIA 
PATIENTS USING MEDICAL CLAIM DATA
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Febrile neutropenia (FN) is a condition that develops in cancer patients treated with 
myelosuppressive chemotherapy characterized by fever and very low neutrophil 
counts, in general signaling infection. Utilizing claims data can provide a real-world 
perspective on the epidemiology, treatment, outcomes, and costs associated with FN 
in cancer patients. However, identifying true cases of FN in claims data can be prob-
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lematic. There is no single ICD-9 code to identify FN; therefore an algorithm must be 
created to identify FN patients. Previously published algorithms are generally com-
prised of 3 main codes: (1) neutropenia (primary designation (ICD-9 code 288.0)) (2) 
fever (ICD-9 780.6) (3) infection. However, the primary designation of neutropenia 
is only used if there is no clear source of infection. Additionally, infection in the 
neutropenic cancer patient can often be difﬁcult to conﬁrm due to the lack of neutro-
phils and typical clinical symptoms and signs; the febrile response may also be blunted. 
Therefore, the FN algorithm may use neutropenia alone, likely identifying patients 
with neutropenia alone in addition to those with FN. In a study utilizing claims data, 
FN was deﬁned as primary or secondary diagnosis of neutropenia or infection during 
the ﬁrst chemotherapy course; 41% of cancer patient newly initiating chemotherapy 
were classiﬁed as having FN. When the FN deﬁnition was narrowed to primary or 
secondary diagnosis with neutropenia and either 1) fever or 2) infection 4.5% were 
classiﬁed as having FN; when the deﬁnition was broadened to diagnosis with neutro-
penia or fever or infection or a procedure code for infection treatment 64.7% were 
classiﬁed as having FN. There is a strong need to validate the coding associated with 
submitting medical claims for the treatment of FN in cancer patients receiving che-
motherapy in real-world practice in order to utilize claims data to investigate FN.
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OBJECTIVES: We introduce a method whereby the continuous enrollment require-
ment can be removed to increase the sample size and correct for incomplete informa-
tion with an advanced statistical technique. METHODS: The inverse probability 
weighted least squares model is used to estimate the outcomes from a sample that 
does not require continuous enrollment in the inclusion criteria. This method involves 
two steps: probabilities are estimated using a non-parametric approach, and standard 
errors of the outcomes regression are adjusted for the ﬁrst step estimation. RESULTS: 
To demonstrate the technique, we used U.S. claims data. Patients with incidents of 
cases of lung cancer were used. A total of 236 patients were identiﬁed without the 
continuous enrollment requirement of one year after diagnosis. With the continuous 
enrolment requirement, our sample size would be 87. Incomplete cases were more 
likely to have surgery and higher rates of comorbidities. R-squared increased 25% 
with the inverse probability weighted technique. Standard errors decreased with 35% 
and therefore improved the precision of our estimators. CONCLUSIONS: The con-
tinuous enrollment requirement does not have to be applied for pharmacoeconomical 
studies. Results might be biased if there are substantial differences between complete 
and incomplete observations. Even though there are no differences, removing this 
requirement increases the sample size and provides efﬁcient estimators, especially in 
rare events.
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BACKGROUND: Hand-foot syndrome or Hand-Foot skin reaction is a common 
adverse effect of certain chemotherapy agents, such as capecitabine or pegylated 
doxorubicin, where it is estimated to occur in 50% of cases. OBJECTIVES: The aim 
of this study is to develop and validate a hand-foot syndrome-speciﬁc quality of life 
scale in order to be able to measure the impact of the condition on patients and 
secondly to be able to assess the value of certain speciﬁc treatments in this indication 
METHODS: The questionnaire was developed after conducting a series of structured 
interviews with patients with forms of hand-foot syndrome of varying severity, which 
yielded a detailed and rigorous collection of verbatim transcripts. The Pilot-Testing 
are realised. RESULTS: Thirty-one items were identiﬁed, and 14 items were selected 
as being relevant and non-overlapping after initial evaluation. The ﬁrst question in 
the HFS14 addresses which member is affected (hand, foot or both). The second 
question addresses the pain with three possible responses (very, moderately or not 
painful). The 14 items can be organised in 2 modules: the ﬁrst module more speciﬁcally 
assesses the handicap generated by involvement of the “feet” and the second assesses 
the handicap generated by involvement of the “hands”. CONCLUSIONS: The hand-
foot syndrome-speciﬁc HFS14 scale is easy to use and meets the requirements of a 
quality of life scale. This scale now needs to be tested in longitudinal studies (for 
example in clinical trials) to conﬁrm its ability to measure a change in status.
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PATIENT-REPORTED OUTCOMES SUPPORTING ONCOLOGY PRODUCT 
LABELING CLAIMS: TRENDS AND CHALLENGES
Hao Y
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The FDA has advocated the PRO Draft Guidance released in 2006 as the main vehicle 
for evaluating PRO and HRQOL claims in oncology product approvals. Additionally, 
FDA-afﬁliated researchers have identiﬁed factors inhibiting acceptance of HRQOL-
based claims for oncology product labels, including: trial design, missing data, multi-
plicity, and inconsistent ﬁndings of HRQOL data. The views of the FDA on PRO and 
HRQOL claims are extensive per its own guidance, which puts forth detailed, restric-
tive requirements on use. These matters clarify why the FDA has not yet allowed the 
utilization of PRO or HRQOL data as primary evidence to support an oncology 
product approval. In contrast, the EMEA since its establishment in 1995 has con-
ducted authorizations without an explicitly deﬁned approach for evaluating HRQOL 
and other PRO data. Further, a reﬂective paper released in 2005 offered only broad 
recommendations on HRQOL labeling claims. As a result, the importance of HRQOL 
or other PRO data in the review process is based more broadly on its relevance to a 
given drug and overall assessment of the study in the eyes of the reviewers. The varying 
approaches between the FDA and the EMEA partly stem from divergent underlying 
organizational characteristics. The FDA enforces laws regarding medical product 
quality. Alternatively, the EMEA serves as a coordinating body, leaving enforcement 
responsibility to member states. Consequently, the EMEA provides more generic 
advice, whereas the FDA insists on rigorous criteria for conceptual and study design 
issues surrounding PRO claims. Otherwise, the EMEA is more likely to accept use of 
well-established PRO and HRQOL measures, whereas the FDA is inclined to request 
new PRO measures that explicitly satisfy the agency’s most recent evaluative stan-
dards. Finally, the FDA places greater focus on symptom-based endpoints reﬂecting 
the direct consequences of treatment, whereas the EMEA is more willing to accept 
global HRQOL claims.
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MELLITUS: A NESTED CASE-CONTROL STUDY
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OBJECTIVES: To describe the association between the three-year average glycosylated 
hemoglobin (A1C) and cardiovascular outcomes in adults with type 2 diabetes mellitus 
(T2DM). METHODS: In this nested case-control study, 245,346 adults (≥18 years) 
with T2DM were identiﬁed among members of Kaiser Permanente Southern Califor-
nia. Type 2 diabetic patients had at least two ICD-9 diagnosis codes for T2DM (250.
x0, 250.x2) and either A1C > 7.5% or prescriptions for hypoglycemic agents from 
2002–2007. Using hospital records and death certiﬁcates, cases were deﬁned as 
patients with a nonfatal MI, nonfatal stroke, or death due to cardiovascular (CV) 
causes (MI, stroke, heart failure, arrhythmia, sudden cardiac death) in the period 
2005–2007. Four controls from the T2DM pool were matched to each case based on 
age, sex and index date (date of the case deﬁning event). A conditional logistic regres-
sion model was used to estimate the odds-ratio (OR) of cardiovascular events compar-
ing patients with an average A1C ≤ 6 % and those with average A1C > 8% to patients 
with average A1C between 6–8%, considered ‘near A1C target’. A1C categories were 
assigned to each patient based on average A1C over the three years prior to the index 
date. RESULTS: A total of 44,628 controls were matched to 11,157 cases. After 
adjusting for CV related medications, comorbidities, and other confounders, patients 
with an average A1C ≤6% were 50% more likely to experience a CV event than the 
‘near A1C target’ T2DM patients (OR = 1.50, 95% CI 1.33–1.69, p < 0.0001). 
Patients with an average A1C > 8% experienced a 14% increase in odds of a CV event 
(OR = 1.14, 95% CI 1.03–1.26, p = 0.01). CONCLUSIONS: Compared to those with 
mean A1C levels between 6–8%, patients with T2DM who achieved mean A1C levels 
of ≤6% or failed to decrease their A1C below 8% over a 3-year period are at increased 
risk for cardiovascular events.
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OBJECTIVES: To assess the impact of oral antidiabetics agents on weight change in 
Type 2 Diabetes Mellitus (T2DM) patients age 65 years and older. METHODS: An 
electronic medical record, General Electric Centricity research database, containing 
the ambulatory health records of US patients was used to conduct a historical cohort 
study of the T2DM elderly patients identiﬁed by ICD-9 codes, OAD prescription or 
both. Six months of continuous OAD monotherapy activity was required, and study 
period included 395 days pre/210 days post from the index date. Two BMI/weight 
readings were mandated, at baseline, and follow up. Data were analyzed using 
ANOVA with Tukey test to correct for multiple comparisons. RESULTS: A total of 
2720 patients with a primary diagnosis of T2DM were included in the study. The 
overall mean age was 72.7 years. Statistical signiﬁcant differences between users of 
different OADs at baseline were found for diastolic blood pressure (p = 0.0009), and 
age (p < 0.001) The most prescribed OAD medications were metformin (58.9%), 
glipizide (14.52%) and glimepiride (7.76%).The overall mean change in A1C level 
was −0.92 (p < 0.001) units and statistically signiﬁcant differences were found when 
compared Metformin/Glipizide (mean difference 0.51320, 95% CI 0.06411–0.96230). 
The overall mean baseline BMI among all of the OAD groups was 29.08 kg/m². 
Signiﬁcant differences in BMI units change were found for meglitinide users, (-1.27), 
metformin users (-1.06), and the sulfonylureas (-0.14). An average of 3.97 lb weight 
loss for all of the OAD groups was found. Major weight loss was found in the Met-
formin group (-6.41lb), and the Sulfonylureas group reported the least weight loss 
(-0.89lb). CONCLUSIONS: An association was found between the OAD use and 
